GSK is ending development of camlipixant in refractory chronic cough after mixed results across two Phase 3 studies, the company said as it moves away from a program that had drawn blockbuster expectations. The decision follows Calm-1 meeting its primary endpoint at week 12, while Calm-2 missed its targets at week 24 and the 25 mg twice-daily regimen failed to hit key secondary measures. Analysts cited limited efficacy across the late-stage dataset, and GSK reiterated that the “limited efficacy” profile is unlikely to transform patient care. The withdrawal also shifts competitive attention toward alternatives being tested by Trevi Therapeutics in the same space. The setback underscores how late-stage endpoint structure can determine whether P2X3 antagonist strategies translate clinically, particularly when both dosing regimens and timepoints are under scrutiny by regulators and trial designers.